| Cell line name |
BT474 A3 |
|---|
| Synonyms |
BT474-A3 |
|---|
| Accession |
CVCL_YX79 |
|---|
| Resource Identification Initiative |
To cite this cell line use: BT474 A3 (RRID:CVCL_YX79) |
|---|
| Comments |
Population: Caucasian.
Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:2594; CYP19A1.
Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo.
Derived from site: In situ; Breast; UBERON=UBERON_0000310. |
|---|
| Sequence variations |
- Gene fusion; HGNC; HGNC:24618; AHCTF1 + HGNC; HGNC:736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line).
- Gene fusion; HGNC; HGNC:7609; MYO9B + HGNC; HGNC:9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line).
- Gene fusion; HGNC; HGNC:16173; DOK5 + HGNC; HGNC:17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line).
- Gene fusion; HGNC; HGNC:16651; MRPL45 + HGNC; HGNC:16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line).
- Gene fusion; HGNC; HGNC:13178; IKZF3 + HGNC; HGNC:12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line).
- Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Invasive breast carcinoma of no special type (NCIt: C4194) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_0179 (BT-474) |
|---|
| Sex of cell |
Female |
|---|
| Age at sampling |
60Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=20386540; DOI=10.1038/sj.bjc.6605641; PMCID=PMC2856013
Evans A.H., Pancholi S., Farmer I., Thornhill A., Evans D.B., Johnston S.R.D., Dowsett M., Martin L.-A.
EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.
Br. J. Cancer 102:1235-1243(2010) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_YX79
|
|---|
| Encyclopedic resources |
Wikidata; Q93432844
|
|---|
| Entry history |
|---|
| Entry creation | 12-Mar-2020 |
|---|
| Last entry update | 19-Dec-2024 |
|---|
| Version number | 9 |
|---|
